Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies 

Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration

A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial

The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer

Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease

New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population 

Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation 

Research is moving forward to understand the value of this blood-based technology as a prognostic tool 

Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation 

Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer